Research Group Pushes For More Diversity In Clinical Trials
This article was originally published in The Gray Sheet
Executive Summary
Trials conducted for FDA approval of devices and drugs need to be held to more stringent standards for including minorities, older individuals and women, and the agency needs more authority to penalize trial sponsors for noncompliance, according to an April 1 report